TOPICAL APPLICATION OF THE PALM TOCOTRIENOL-RICH FRACTION (TRF) ENHANCES CUTANEOUS WOUND HEALING IN TYPE 2 DIABETIC MICE

ZAIZUHANA SHAHRIM1,2; SUZANA MAKPOL2; GEEK CHIN TAN3; NURUL AISHAH MUHAMMAD1 and ZAFARIZAL ALDRIN AZIZUL HASAN1

ABSTRACT
Type 2 diabetic (T2D) wounds are characterised by excessive, persistent inflammation and oxidative stress, resulting in delayed healing. The tocotrienol-rich fraction (TRF) has potential as a therapeutic agent in improving diabetic wounds due to its anti-inflammatory and antioxidative effects. Thus, we aimed to evaluate the effect of the TRF on diabetic cutaneous wounds using a T2D mouse model. Full-thickness wounds were made on the backs of mice, and the TRF formulation was topically applied. The effect of the TRF was evaluated by examining wound closure, histology, CD31 immunohistochemistry and collagen deposition with Masson’s trichrome staining. Biochemical assessments of catalase (CAT), glutathione peroxidase (GPx), myeloperoxidase (MPO), protein levels, transforming growth factor beta-1 (TGF-β1), metalloproteinase-9 (MMP-9) and cytokine production were performed. The results showed that TRF treatment enhanced wound closure and healing in the T2D mouse wounds. The TRF increased CAT, GPx, protein, hydroxyproline and TGF-β1 levels but reduced MPO activity and MMP-9 production in diabetic wounds. Multiplex immunoassay revealed that the TRF modulated proinflammatory cytokine and chemokine production. However, it increased interleukin-4 (IL-4) and vascular endothelial growth factor (VEGF) production and reduced granulocyte-macrophage colony-stimulating factor (GM-CSF). Our data suggest that topical TRF application may enhance diabetic cutaneous wound healing.

Keywords: diabetic mice, diabetes mellitus, skin, tocotrienol-rich fraction, wound healing.

Received: 26 April 2021; Accepted: 15 November 2021; Published online: 5 January 2022.

INTRODUCTION
The most common type of diabetes is type 2 diabetes (T2D) mellitus (Tsalamandris et al., 2019). T2D patients have a greater risk of limb amputation than nondiabetic individuals due to impaired wound healing (Zheng et al., 2018). Wound healing is multifactorial, and it requires homeostasis, inflammation, proliferation, and tissue remodelling (Rodrigues et al., 2019; Thangavel et al., 2018; Xiao et al., 2020). However, wound healing is delayed in diabetic patients for many reasons, including persistent inflammatory and high oxidative stress states, resulting in abnormal angiogenesis and...
Although inflammation is an essential part of healing, disproportionate inflammation leads to disruptions in the normal healing cascade (Strang et al., 2020; Zhao et al., 2016), such as in the skin of diabetic mice (Brandt et al., 2018). Inflammation and the immune system are modulated by cytokines and extracellular signalling proteins (Fields et al., 2019). Dysregulated production of these proteins results in impaired diabetic wound healing (Strang et al., 2020). Thus, regulating inflammation through its mediators and increasing antioxidative activities may improve cutaneous wound healing in diabetic patients (Zhao et al., 2016).

A study performed on diabetic patients showed reductions in catalase (CAT) and glutathione peroxidase (GPx) activities and an overall decrease in antioxidant levels (Alghazeer et al., 2018). The reduction in antioxidant defence, which is one of the detrimental effects of reactive oxygen species (ROS) on cellular homeostasis, often worsens redox imbalance (Cano Sanchez et al., 2018). Diabetic complications mainly occur when ROS production induced by diabetes stimulates various pathological signalling pathways that lead to tissue injury (Deng et al., 2021; Zhao et al., 2016). Therefore, increasing antioxidative activity may enhance wound healing (Zhao et al., 2016).

During inflammation or oxidative stress, neutrophils secrete a certain amount of myeloperoxidase (MPO) to help recover from tissue injury (Khan et al., 2018). While excessive MPO activity is detrimental to tissue recovery, MPO is an important indicator of inflammation and the oxidative stress response (Khan et al., 2018). The structural protein, collagen is essential for tissue regeneration and dermal reconstruction (Thangavel et al., 2017), and collagen deposition in the wound can be indicated by hydroxyproline content (Hemmati et al., 2018).

It was previously reported that low transforming growth factor beta (TGF-β) levels can predict the chronicity of diabetic wounds (Liarte et al., 2020). Transforming growth factor beta-1 (TGF-β1) is known to stimulate collagen production in dermal fibroblasts to achieve wound contraction (Serra et al., 2017) and closure. In contrast, metalloproteinase-9 (MMP-9) leads to excessive degradation of the extracellular matrix and reduces the tensile stress of the wound. MMP-9 is highly expressed in diabetic wounds (Ayuk et al., 2016) and is considered the primary cause of diabetic foot ulcer recalcitrance in healing (Jones et al., 2019). Thus, this proteinase would be an excellent candidate in a study regarding the treatment of diabetic wounds.

The tocotrienol-rich fraction (TRF) is a blend of tocotrienol (~70%) and alpha-tocopherol (~30%). It has been reported that the tocotrienol/tocopherol ratios in rice bran oil, barley, and palm oil are 1:1, 1.9:1, and 3:1, respectively (Cheng et al., 2017). As a rich source of vitamin E, the TRF has an abundance of antioxidative (Khor et al., 2017; Matough et al., 2014; Shahidi and De Camargo, 2016) and anti-inflammatory (Nor Azman et al., 2018; Yap, 2018) properties. No adverse skin reactions after the topical application of tocotrienols have been reported (Hasan et al., 2018). Wound recovery in diabetic (streptozotocin-induced) and normal rats could be enhanced by the TRF (Elsy et al., 2017, Musalmah et al., 2005), and topical treatment with the TRF could also promote burn healing (Elsy et al., 2017). Despite years of research, the pathogenesis of impaired cutaneous wounds in T2D patients remains incompletely understood, and there is still a need to identify therapeutic approaches and remedies for wounds. Furthermore, alternative therapeutic treatments using natural products are in high demand. In view of the background of the TRF and to the best of our knowledge, studies using the TRF in T2D skin wound healing are very limited. Therefore, the current study aimed to evaluate cutaneous wound healing in a T2D model that was topically treated with the TRF.

MATERIALS AND METHODS

Reagents

In this study, palm-based TRF Gold Tri E 70 was purchased from Sime Darby Food and Beverages Marketing Sdn. Bhd. (Selangor, Malaysia). The TRF (10%, w/w) was loaded in vehicle consisting of PEG-400 (85%, w/w, Sigma-Aldrich, USA, Cat No. 202398) with Tween® 80 (5% w/w, Polysorbate, Sigma-Aldrich, USA, Cat No. 59924).

Diabetic and Normal Mouse Models

Type 2 diabetic (T2D) and obese (B6. V-Lepob/ob)Rj) male mice were obtained from Janvier Laboratory (France), and lean male mice (C57BL/6) were used as the normal control. The levels of fasting blood glucose and serum insulin were determined using an Accu-Chek device (Roche, GmbH, Mannheim, Germany) and ELISA (Rat/ Mouse Insulin Kit; Millipore, St. Charles, MO, USA) to validate the development of diabetes in the mouse models. Mice with blood glucose exceeding 300 mg dL⁻¹ were considered hyperglycaemic. The body weights of the mice were recorded at every postinjury time point. All procedures were strictly performed based on the approved protocols by the Universiti Kebangsaan Malaysia Animal Care and Use Committee (UKMAEC, procedure number: BIOK/PP2017/SUZANA/25-JAN./817-JAN.-2017-SEPT.-2018). The mice were subjected to a cutaneous...
wounding experiment and randomly divided into three groups of 12 mice.

Group I: Normal control (wild-type, received vehicle only)
Group II: T2D control (received vehicle only)
Group III: T2D treated (received TRF in vehicle)

Cutaneous Wound Model with Full-thickness Skin Excision

Four full-thickness skin excision wounds were made on the dorsum of the mice using a sterile 5 mm punch biopsy (Kai Medical, Japan) under anaesthesia (sodium pentobarbital, 60 mg kg$^{-1}$). Subsequently, a silicone wound splint (Grace Bio-Labs Oregon, USA) was used to secure the wound perimeter and prevent contraction. Topical application of the TRF was performed twice daily, and the wounds were covered with a transparent dressing (Tegaderm, 3M Health Care, St. Paul, MN, USA Cat. No. 1624) after the treatment. All mice were kept in a controlled environment at a temperature of 21 ± 0.5°C, relative humidity of 50 ± 10%, and a 12-hr alternating light and dark schedule. Water and food were provided ad libitum.

Measurement of Wound Closure Kinetics

Images of the wounds were captured on days 0, 1, 3, 7 and 14 using a digital camera beginning on the first day of skin excision until day 14. Images were examined using image processing software (ImageJ, version 1.5e, NIH, USA). The percentage of wound closure was calculated as follows:

$$\% \text{ wound closure} = \frac{\text{initial wound area (day 0)} - \text{wound area at n}}{\text{wound area day 0}} \times 100$$

where, $n$ = number of days (0, 1, 3, 7 and 14) after skin excision.

Histopathological and Immunohistochemical Examination of Wound Tissues

Excised wound tissues were prepared for clinical pathology on the indicated days postinjury. The tissues were fixed with buffered formalin (10%) obtained from Sigma-Aldrich (USA) and dehydrated before being converted into paraffin-embedded blocks. Tissue sections with a thickness of 4 μm were prepared and stained with haematoxylin and eosin (H&E) (Leica, Germany) to assess cellular responses to the treatments and stained with Masson’s trichrome on day 14 to observe collagen deposition in the wound tissue according to the manufacturer’s protocol. A semiquantitative method was used to examine the following processes: inflammatory cell infiltration, epidermal regeneration (re-epithelialisation), fibroblast proliferation and collagen deposition. Three stained sections in each group were evaluated and scored using a scale, as summarised in Table 1. To detect the presence of CD31, immunohistochemistry was conducted. Briefly, the sections were blocked with 3% BSA at 37°C for 30 min, followed by incubation with CD31 antibodies (1:100, goat, Servicebio, GB13063) at 4°C overnight. After being washed with phosphate buffered saline (PBS), a goat anti-rabbit secondary antibody (Servicebio, GB23204, 1:200) coupled with horseradish peroxidase was added. The samples were incubated at 37°C for 1 hr. The sections were stained with 10% diaminobenzidine tetrahydrochloride (Servicebio, G1211) and lightly counterstained with haematoxylin. Positive immunohistochemical staining was observed as brown staining. The number of blood vessels in three tissue sections was assessed using the microvessel density (MVD) counting technique, whereby the average number of microvessels per high-power field (HPF) was estimated by counting CD31-stained cells. All sections were examined using a digital microscope (Eclipse 200, Nikon Instruments, Inc., Melville, NY) and evaluated by pathologists in a single-blind manner.

Determination of CAT, GPx and MPO Activities in Wound Tissues

CAT and GPx activities were assessed using kits from Cayman Chemical (Ann Arbor, MI, USA), whereas MPO was assessed using kits from (BioVision Inc., USA) according to the manufacturer’s protocol.

Protein and Hydroxyproline Measurement

Protein and hydroxyproline levels in wound tissues were measured using commercial assay kits.

<table>
<thead>
<tr>
<th>TABLE 1. HISTOLOGICAL FEATURES AND SCORING</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Histological score</strong></td>
</tr>
<tr>
<td>Presence of inflammatory cells</td>
</tr>
<tr>
<td>Fibroblast proliferation</td>
</tr>
<tr>
<td>Epidermal regeneration</td>
</tr>
<tr>
<td>Collagen</td>
</tr>
</tbody>
</table>
from Cayman Chemical (Ann Arbor, MI, USA) and BioVision Inc. (USA), respectively, according to the manufacturer’s instructions.

Measurement of MMP-9 and TGF-β1 Levels in Granulation Tissues

MMP-9 and TGF-β1 levels in wound tissues were examined using a Fine Test ELISA kit for mice from Wuhan Fine Biotech Co., Ltd. (Wuhan, China) per the manufacturer’s protocols.

Multiplex Cytokine Analysis

A custom-made multiplex analysis was performed based on xMAP Luminex technology using a ProcartaPlex™ cytokine 36 plex assay from Thermo Fisher Scientific Inc. according to the manufacturer’s protocol. Measurements were performed using Luminex 200 with xPONENT® software version 3.1, and the concentration of cytokines was determined using MasterPlex QT software version 2.0.0.59.

Statistical Analysis

All experiments were conducted in replicates. The data were subjected to statistical analysis using the Statistical Package for Social Sciences (SPSS) version 22. A \( p \) value less than 0.05 was considered significant.

RESULTS AND DISCUSSION

All diabetic mice had significantly higher \( (p<0.01) \) body weights throughout the study duration than those in the normal control group \( (Figure\ 1a) \). For example, the mean measurement for the T2D control group was 41.33 ± 0.84 g on day 1 and 43.06 ± 0.26 g on day 14 and that for the TRF-treated group was 41.75 ± 0.10 on day 1 and 42.98 ± 0.60 g on day 14. Moreover, normal control mice exhibited body weights of 26.24 ± 0.60 g on day 1 and 27.33 ± 0.45 g on day 14 \( (Figure\ 1a) \). Blood glucose levels were significantly \( (p<0.01) \) higher in the T2D control group \( (362.67 ± 5.24\text{ mg dl}^{-1}\text{ (day 1) and }372.00 ± 4.16\text{ mg dl}^{-1}\text{ (day 14)} \) and the TRF-treated group \( (355.00 ± 9.54\text{ mg dl}^{-1}\text{ (day 1) and }377.33 ± 5.80\text{ mg dl}^{-1}\text{ (day 14)} \) than in the normal control group \( (120.00 ± 12.70\text{ mg dl}^{-1}\text{ (day 1 and }151.70 ± 13.70\text{ mg dl}^{-1}\text{ (day 14)} \) \( (Figure\ 1b) \). The normal control group also exhibited significantly \( (p<0.01) \) lower serum insulin levels on day 1 (1.67 ± 0.03 ng ml\(^{-1}\)) and day 14 (1.54 ± 0.13 ng ml\(^{-1}\)) than the diabetic control group (3.62 ± 0.22 ng ml\(^{-1}\)) on days 1 and 14 (3.70 ± 0.03 ng ml\(^{-1}\)). TRF-treated mice also showed significantly lower \( (p<0.01) \) insulin levels on day 1 (3.66 ± 0.04 ng ml\(^{-1}\)) and day 14 (3.75 ± 0.02 ng ml\(^{-1}\)) than those in the normal control group \( (Figure\ 1c) \).

Wound Closure and Histological Effects of the TRF on Cutaneous Wound Healing

**Wound kinetics and macroscopic assessments.** Wound kinetic and macroscopic assessments of all mice were measured on days 0, 1, 3, 7 and 14, and the excised wound site was photographed as shown in \( Figure\ 2 \). Normal control mice showed the fastest wound closure rate, and the wounds were completely closed \( (100\%) \) on day 14 with visible hair growth. In contrast, T2D controls showed significantly slower \( (p<0.01) \) rates at days 3, 7 and 14 than the normal controls. However, TRF-treated wounds showed significantly higher \( (p<0.05) \) wound closure rates on days 3, 7 and 14 than T2D control wounds \( (Figure\ 2b) \).

**Histological assessments.** Previous findings were consistent with the histological examination \( (Figure\ 3a) \). Wound sections in all groups showed the presence of inflammatory cells on day 3. These immune cells are the key regulators and players during acute wound healing and prevent infection \( (Peiseler\ and\ Kubes,\ 2019) \). Immune cell infiltration is followed by alterations from a proinflammatory to

![Figure 1](https://example.com/figure1.png)

*Figure 1. (a) Body weights, (b) blood glucose levels, and (c) insulin levels of the mice. The data are expressed as the mean ± SEM \( (n=3) \) and were analysed using two-way ANOVA with Tukey’s multiple comparison test. *\( p<0.01 \) compared with the normal control group.*
TOPICAL APPLICATION OF THE PALM TOCOTRIENOL-RICH FRACTION (TRF) ENHANCES CUTANEOUS WOUND HEALING IN TYPE 2 DIABETIC MICE

Figure 2. Effects of the TRF on wound closure. (a) Representative images of the gross appearance of wounds, and (b) the percentage of wound closure. The wound closure data are the mean ± SEM (n=3, 12 wounds/group) and were calculated by two-way ANOVA with Tukey’s multiple comparison test.  

*a p<0.01 vs. the normal control, *b p<0.05 vs. the T2D control.

Figure 2. Effects of the TRF on wound closure. (a) Representative images of the gross appearance of wounds, and (b) the percentage of wound closure. The wound closure data are the mean ± SEM (n=3, 12 wounds/group) and were calculated by two-way ANOVA with Tukey’s multiple comparison test.  

*a p<0.01 vs. the normal control, *b p<0.05 vs. the T2D control.

a healing immune response to inhibit inflammation and initiate the tissue remodelling process (Raziyeva et al., 2021).

In the present study, the normal control wound exhibited standard healing stages, whereby thin re-epithelialisation was observed as early as day 3 after wounding and continued until day 7. The wound surface was also fully covered on day 14. In addition, the presence of more fibroblasts and blood vessels was also evident in the normal control group than in the other groups. In contrast, the T2D controls showed an abundance of inflammatory cells and disorganised structures, but TRF-treated wounds showed a moderate inflammatory response compared to diabetic controls.

On day 7, the T2D control group showed marked dominance of inflammatory cells with few fibroblasts, but in TRF-treated wounds, the inflammatory cells seemed to subside, and the wounds showed well-formed granulation tissue, which was covered by more blood vessels and fibroblasts with some collagen deposition than those in the T2D control. On day 14, the wound sections in the diabetic control group showed the presence of blood vessels and were dominated by inflammatory cells compared to TRF-treated wounds, whereby thicker granulation tissue was dominated by fibroblasts with adequate, more organised, and compact collagen deposition and a completely newly regenerated epithelial layer.

In addition, histological scoring of inflammation, fibroblast proliferation, re-epithelialisation and collagen deposition was performed (Figure 3b). The results showed that the proportion of inflammatory cells was significantly reduced at days 3 (p<0.01), 7 (p<0.05) and 14 (p<0.05) in TRF-treated wounds compared to T2D control wounds. Moreover, the rate of fibroblast proliferation was significantly increased in TRF-treated diabetic wounds on days 3 (p<0.05), 7 (p<0.01) and 14 (p<0.001) compared with diabetic wounds. The T2D control group demonstrated incomplete re-epithelialisation and poorly formed granulation tissue, but TRF-treated wounds showed significantly higher epidermal regeneration on days 3 (p<0.05), 7 (p<0.001) and 14 (p<0.01) with denser collagen deposition on days 7 (p<0.01) and 14 (p<0.001) than the diabetic control (Figure 3b). We showed that T2D wounds sustained production of inflammatory cells in the wound sites, which blocked the progression of healing, thus, impeding wound closure (Tan et al., 2019). Dysfunctional fibroblasts and epidermal cells, failed angiogenesis and impaired tissue maturation (Daemi et al., 2019; Manzouerh et al., 2019; Thangavel et al., 2017) were observed in this group.

Diabetic wound healing is impaired due to improper angiogenesis (Okonkwo and DiPietro, 2017). To understand the effect of the TRF on angiogenesis, the wound sections were stained with CD31 (Figure 3c) and quantified (Figure 3d). The diabetic controls showed a few immature blood vessels compared to normal controls and TRF-treated wounds on days 7 and 14. A few densely packed vessels were also observed. In comparison to the T2D control, TRF treatment significantly (p<0.001) increased the number of CD31-positive cells on days 7 and 14.

Collagen is the major component of the extracellular matrix, which is essential for wound closure. Collagen synthesis, deposition, remodelling
and maturation are crucial during tissue repair and regeneration (Thangavel et al., 2017). Collagen biosynthesis in tissue sections was examined by Masson’s trichrome staining (Daemi et al., 2019; Zadeh Gharaboghaz et al., 2020) on day 14 (Figure 3e). The results showed that granulation tissues in TRF-treated diabetic wounds exhibited collagen densities that were similar to those of normal wound healing. Treatment with the TRF induced significantly higher collagen synthesis and deposition than diabetic control wounds. This result suggests that topical application of the TRF may improve collagen synthesis, maturation and deposition.

Protein and Hydroxyproline Levels in Wound Tissues

Protein and hydroxyproline levels were measured on days 7 and 14 (Table 2). The level of protein indicates the cellular proliferation rate in the wound site (Lin et al., 2012). The protein level in the T2D control group was significantly lower ($p<0.05$) than that in the normal control on days 7 and 14. However, TRF treatment significantly increased ($p<0.01$) the protein level on days 7 and 14 ($p<0.05$) compared to that in the T2D control. The hydroxyproline level was also significantly reduced ($p<0.001$) on days 7 and 14 in the T2D group compared to the normal control. However, TRF-treated wounds showed a significant ($p<0.001$) increase in hydroxyproline on days 7 and 14. The concentration of hydroxyproline reflects the collagen concentration in tissue, and a higher concentration indicates a faster rate of wound healing, providing the tissue matrix with integrity and strength (Dwivedi et al., 2017). A high hydroxyproline level also indicates an increase in cellular proliferation and collagen synthesis (Dwivedi et al., 2017).

---

![Histology score comparison](image)
TOPICAL APPLICATION OF THE PALM TOCOTRIENOL-RICH FRACTION (TRF) ENHANCES CUTANEOUS WOUND HEALING IN TYPE 2 DIABETIC MICE

Effect of the TRF on TGF-β1 and MMP-9 Levels

TGF-β, a transforming growth factor, plays a critical role in each phase of wound healing by suppressing the inflammatory response and supporting granulation tissue development at the wound site (Wang et al., 2017). A significant reduction (p<0.001) in TGF-β1 levels was observed in T2D control wound tissue compared to normal control wound tissue on days 7 and 14. However, TRF treatment significantly (p<0.001) increased the level of TGF-β1 on days 7 and 14 compared to that in the diabetic control.

High levels of MMP-9 in diabetic wounds often lead to excessive degradation of the extracellular matrix and reduced tensile strength of the wound (Ayuk et al., 2016). Our data showed significantly higher (p<0.001) concentrations of MMP-9 in T2D control wounds than in normal control wounds on days 7 and 14. However, treatment with the TRF significantly decreased MMP-9 production on days 7 and 14 (p<0.001) compared to those in the diabetic control (Table 2).

The TRF Reduces Oxidative Stress in Diabetic Wounds

The first line of defence against oxidants during injury involves the antioxidants CAT and GPx (Ighodaro and Akinloye, 2018; Kurahasi and Fujii, 2015). In the present study, the T2D control group showed significantly lower (p<0.05) CAT activity on days 7 and 14 than the normal control group. However, TRF treatment significantly increased CAT activity on days 7 (p<0.01) and 14 (p<0.05) compared to that in the T2D control (Figure 4a). The T2D control group showed significantly (p<0.05) lower GPx activity on days 7 and 14 postinjury than the normal controls. In contrast, TRF-treated wounds showed significantly (p<0.05) higher GPx activity on day 14 than T2D control wounds (Figure 4b). The TRF has also been reported to increase other antioxidants, such as superoxide dismutase (SOD) and glutathione (GSH), but reduce lipid peroxidation in T2D wounds (Shahrim et al., 2016; 2019).

Myeloperoxidase protects against infection during injury by killing pathogens. It also acts as...
Table 2. Effect of the TRF on Protein, Hydroxyproline, TGF-β1 and MMP-9 Levels

<table>
<thead>
<tr>
<th>Group</th>
<th>Protein content (μg 100 mg⁻¹ tissue)</th>
<th>Hydroxyproline (μg 100 mg⁻¹ tissue)</th>
<th>TGF-β1 (pg ml⁻¹)</th>
<th>MMP-9 (pg ml⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Day 7</td>
<td>Day 14</td>
<td>Day 7</td>
<td>Day 14</td>
</tr>
<tr>
<td>Normal ctrl</td>
<td>69.23 ± 4.96</td>
<td>54.06 ± 5.96</td>
<td>234.03 ± 4.59</td>
<td>127.34 ± 0.653</td>
</tr>
<tr>
<td>T2D ctrl</td>
<td>48.78 ± 6.55</td>
<td>51.37 ± 5.91</td>
<td>47.42 ± 0.38</td>
<td>54.60 ± 0.38</td>
</tr>
<tr>
<td>T2D+TRF</td>
<td>63.76 ± 5.16</td>
<td>70.83 ± 3.95</td>
<td>185.40 ± 4.94</td>
<td>134.51 ± 5.32</td>
</tr>
</tbody>
</table>

Note: The values are expressed as the mean ± SEM (n=3) of the level of protein, hydroxyproline, TGF-β1, and MMP-9 and were analysed using two-way ANOVA with Tukey’s multiple comparison test. *p<0.05, †p<0.01, ‡p<0.001 vs. the normal control. „p<0.05, „p<0.01, †p<0.001 vs. the T2D control.

Cytokine Profile of T2D Wounds Treated with the TRF

A multiplex protein array was carried out to determine the effects of TRF on cytokine levels in tissue collected from wounds on days 1, 3, 7 and 14. This analysis included the proinflammatory interleukin family (IL-1α and IL-17A), leukaemia inhibitory factor (LIF) and interleukin-4 (IL-4), which are anti-inflammatory markers. The chemokines analysed included eotaxin, monocyte chemoattractant protein-1 (MCP-1), MCP-3, macrophage inflammatory proteins-1 alpha (MIP-1α), regulated upon activation, normal T cell expressed and presumably secreted (RANTES), LIX/CXCL-5 (C-X-C motif chemokine 5), growth regulated oncogene (GRO-α), macrophage inflammatory protein-2 (MIP-2) and interferon gamma-induced protein 10 (IP-10). Growth factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and vascular endothelial growth factor (VEGF) were also examined.

Inflammatory mediators are mostly synthesised de novo by activated cells in response to wounding (Chang et al., 2018). Chronic wounds are in a persistent inflammatory state, as indicated by excessive inflammatory mediator release (Ligi et al., 2016). Profound increases in proinflammatory cytokines (IL-1α, IL-17A, and LIF) were observed in T2D wounds compared to normal controls (Figures 5a–c). Our results showed that treatment with the TRF significantly abated proinflammatory cytokine production, particularly that of IL-1α, on day 1 (<0.001), day 3 (<p<0.05), day 7 (<p<0.05), and day 14 (<p<0.01) (Figure 5a). IL-17A was also reported to be involved in the pathogenesis of chronic wounds (Hadian et al., 2019). This study showed that TRF treatment significantly mitigated IL-17A at day 7 (<p<0.05) compared to that in the diabetic control (Figure 5b). Moreover, LIF, a cytokine belonging to the IL-6 family, was significantly increased in the T2D group; however, the TRF-treated group exhibited a
reduction in LIF on day 1 ($p<0.05$), day 3 ($p<0.001$), and day 7 ($p<0.001$) compared to the diabetic control (Figure 5c).

IL-4 production was significantly increased in TRF-treated wounds on day 1 ($p<0.01$), day 3 ($p<0.05$), and day 7 ($p<0.05$) compared to that in T2D control wounds (Figure 5d). This anti-inflammatory marker significantly contributes to the healing process in wounds by promoting neuronal and glial survival by inhibiting the local response to inflammation, as well as signalling nerve growth factor production and GM-CSF, which are beneficial for diabetic peripheral neuropathy (Zhao et al., 2016).

Our findings also showed a significant increase ($p<0.05$) in eotaxin in TRF-treated wounds on days 3, 7 and 14 compared to T2D control wounds (Figure 6a). This increase might be related to the function of eotaxin, a chemotactic protein that attracts eosinophils and promotes collagen deposition, angiogenesis, and mitogenesis during injury (Burns et al., 2020). Eotaxin is a proinflammatory chemokine, is a small chemotactic cytokine that is secreted by a variety of cells in the wound (Ridiandries et al., 2018) and functions to regulate the migration of cells to the injured area (Sokol and Luster, 2015). The chemokines MCP-1 and MIP-2 are known to modulate postinfection inflammation and tissue lesions (Fan et al., 2021). However, overexpression of these biomolecules in the wounds of diabetic patients may amplify tissue permeability and leucocyte intrusion, leading to chronic inflammation in the surrounding normal skin and subsequently hindering wound recovery (Fan et al., 2021).

Similarly, significant reductions in MCP-1 were observed on day 3 ($p<0.001$) compared to those in the T2D control (Figure 6b). MCP-3 has been reported to be a negative regulator of cutaneous inflammation, and its upregulation has been correlated with various inflammatory conditions, such as infection, the tumour microenvironment, and cardiovascular disease (Ford et al., 2019). Our data showed that MCP-3 production was reduced by the TRF on day 3 ($p<0.05$), days 7 ($p<0.01$) and 14 ($p<0.05$) compared to the T2D control (Figure 6c). However, treatment with the TRF significantly ($p<0.05$) increased MIP-1α on days 1, 3 and 7 compared to that in the T2D control (Figure 6d). This chemokine is often found to be increased in foot ulcer patients (Van Asten et al., 2017). Additionally, MIP-2 was significantly increased on day 1 ($p<0.05$), day 7 ($p<0.01$), and day 14 ($p<0.05$) compared to those in the T2D control (Figure 6e).

Figure 5. (a-c) Changes in proinflammatory, and (d) anti-inflammatory cytokines in wound tissues in response to TRF. The data are the mean ± SEM ($n=3$) and were calculated using two-way ANOVA with Tukey’s multiple comparison test. *$p<0.05$, **$p<0.01$, ***$p<0.001$ vs. the normal control; $\#p<0.05$, $\&p<0.01$, $\$p<0.001$ vs. the T2D control.
Figure 6. Changes in chemokines in skin wound tissues in response to TRF. The data are the mean ± SEM (n=3) and were calculated using two-way ANOVA with Tukey’s multiple comparison test. *p<0.05, **p<0.01, ***p<0.001 vs. the normal control; †p<0.05, ‡p<0.01 vs. the T2D control.
Moreover, the inflammatory chemokine IP-10 has been reported to be increased in diabetic patients due to inflammation induced by oxidative stress (Fatehi et al., 2015). TRF treatment significantly reduced IP-10 (p < 0.05) on day 3 compared to that in the T2D control (Figure 6f). Higher GRO-α production was observed on days 3 (p < 0.001) and 7 (p < 0.001) in T2D controls than in normal controls (Figure 6g). Interestingly, a significant reduction was observed in TRF-treated wounds on days 1 (p < 0.05), 3 (p < 0.01) and 7 (p < 0.01) compared to diabetic control wounds.

RANTES and LIX have been reported to be crucially associated with impaired wound healing (Ligi et al., 2016). Low levels of RANTES have been reported to enhance the inflammatory response in venous leg ulcers (VLUs) throughout the healing process in the wound (Ligi et al., 2016). TRF treatment significantly decreased RANTES levels in diabetic mice on day 1 (p < 0.05), day 7 (p < 0.01), and day 14 (p < 0.05) compared to the T2D control (Figure 6h). A significant decrease in LIX was observed in the TRF-treated group on day 3 (p < 0.05), day 7 (p < 0.001), and day 14 (p < 0.05) compared to the T2D control (Figure 6i).

Activation of granulocyte and macrophage lineages is initiated by the pleiotropic cytokine GM-CSF (Rho et al., 2015), which triggers the proliferation of monocytes and granulocytes (neutrophils, eosinophils and basophils) (Bhattacharya et al., 2015; Weston et al., 2018). Due to these effects, an imbalance in GM-CSF production/signalling through ERK1/2 and NFκB activation (Bhattacharya et al., 2015) may lead to harmful inflammatory conditions (Lotfi et al., 2019). Initially, this cytokine was low on day 1 (p < 0.01) and then increased on day 3 (p < 0.001) and day 7 (p < 0.01) in T2D controls compared with normal controls (Figure 7a). Treatment with TRF elevated GM-CSF levels on day 1 (p < 0.01), but these levels declined on day 3 (p < 0.01) and increased again on days 7 and 14 (p < 0.05) compared to those of the T2D controls (Figure 7a).

VEGF is known to initiate wound healing and promote expansion of the vascular network (DiPietro, 2016; Zhou et al., 2017) throughout granulation tissue that is essential for providing oxygen, immune cells and nutrients to aid wound healing (Hutchings et al., 2021). This study showed that the production of VEGF in diabetic group was significantly decreased on day 1 (p < 0.01), day 3 (p < 0.001), day 7 (p < 0.01), and day 14 (p < 0.05) compared to that in the normal control (Figure 7b). However, treatment with the TRF significantly increased VEGF production on day 1 (p < 0.05), day 3 (p < 0.01), day 7 (p < 0.05) and day 14 (p < 0.05) compared to that in the T2D control. The increase in VEGF production suggests its role in facilitating angiogenesis, thus, promoting the formation of more blood vessels and improving blood flow in the wound area (Johnson and Wilgus, 2014).

There have been several studies on the efficacy of the TRF mediated by a variety of pharmacological activities, including antioxidant (Ahsan et al., 2014), anti-inflammatory and wound healing activities (Elsy et al., 2017). In the present study on T2D diabetic mice, topical application resulted in the acceleration of wound closure, improved re-epithelialisation and increased formation of granulation tissue, which consists of various cells, vascular capillaries and loose connective tissues to fill the injured space (Karim et al., 2021; Tan et al., 2019). Moreover, marked collagen synthesis and deposition with high levels of hydroxyproline...
were observed in TRF-treated diabetic wounds. These results may be due to decreased production of proinflammatory cytokines and metalloproteinases, and increased levels of growth factors released by cells to induce the proliferation and migration of keratinocytes, macrophages, and fibroblasts into the wound space (Rousselle et al., 2019; Tan et al., 2019; Yamakawa and Hayashida, 2019). We also observed increases in anti-inflammatory cytokines and antioxidant enzymes at the wound site in diabetic mice. Based on these findings, we proposed a schematic illustration of the potential mechanism by which TRF enables successful healing of wounds in a T2D mouse model (Figure 8) due to the anti-inflammatory and antioxidant potential of the TRF.

**CONCLUSION**

Topical application of the TRF promotes wound repair in the cutaneous wounds of T2D mice. The results of our study demonstrated that topical TRF application accelerated cutaneous wound repair in T2D mice by elevating the levels of antioxidant enzymes such as CAT and GPx and cytokines such as IL-4, reducing MPO, and modulating proinflammatory cytokines, such as IL-1α, IL-17A, and LIF, chemokines (GRO-α, MCP-1, -3, RANTES, IP-10) and GM-CSF in T2D wounds. Moreover, eotaxin, MIP-1α, -2, IL-4, VEGF and TGF-β1 levels were elevated in TRF-treated T2D wounds, which accelerated the progression of healing. Thus, the findings of this study suggest the benefits and
potential use of the TRF as a therapeutic agent to treat cutaneous wounds in T2D patients.

ACKNOWLEDGEMENT

The authors would like to acknowledge the Director-General of the MPOB for permission to publish this article.

REFERENCES


Brandt, S L; Wang, S; Dejani, N N; Klopfenstein, N; Winfree, S; Figuieras, L; McCarthy, B P; Territo, P R and Serezani, C H (2018). Excessive localized leukotriene B4 levels dictate poor skin host defense in diabetic mice. JCI Insight, 3(17): e120220.


Ford, J; Hughson, A; Lim, K; Bardina, S V; Lu, W; Charo, I F; Lim, J K and Fowell, D J (2019). CCL7 is a negative regulator of cutaneous inflammation following Leishmania major infection. Front. Immunol., 9: 3063.


Hutchings, G; Kruszyna, Ł; Nawrocki, M J; Strauss, E; Bryl, R; Spaczyńska, J; Perek, B; Jemielity, M; Mozdziak, P; Kemptisty, B; Nowicki, M and Krasinski, Z (2021). Molecular mechanisms associated with ROS-dependent angiogenesis in lower extremity artery disease. Antioxidants, 10(5): 735.


Wang, L; Qin, W; Zhou, Y; Chen, B; Zhao, X; Zhao, H; Mi, E; Mi, E; Wang, Q and Ning, J (2017). Transforming growth factor β plays an important role in enhancing wound healing by topical application of Povidone-iodine. *Sci. Rep.*, 7(1): 991.


Yuan, Y; Das, S K and Li, M (2018). Vitamin


